Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Shanmuganathan N, Yeung DT, Wadham C, Fernandes A, et al. Blood 2025;146:2821-2832.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Shanmuganathan N, Yeung DT, Wadham C, Fernandes A, et al. Impact of ASXL1 at diagnosis in patients with CML receiving frontline potent TKIs: high risk of kinase domain mutations. Blood 2025;146:2821-2832.
PMID: 40896831